Novo Nordisk AS
NVO
Company Profile
Business description
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Contact
Novo Alle 1
Bagsvaerd2880
DNKT: +45 44448888
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
69,500
Novo Nordisk AS News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
stocks
3 ‘buy the dip’ candidates with wide moats
Does recent share price weakness spell opportunity in these three high-quality companies?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,919.40 | 32.70 | -0.37% |
| CAC 40 | 8,056.38 | 56.19 | -0.69% |
| DAX 40 | 24,350.28 | 11.65 | 0.05% |
| Dow JONES (US) | 49,704.47 | 95.31 | 0.19% |
| FTSE 100 | 10,269.43 | 36.36 | 0.36% |
| HKSE | 26,486.63 | 79.79 | 0.30% |
| NASDAQ | 26,274.13 | 27.05 | 0.10% |
| Nikkei 225 | 62,784.12 | 366.24 | 0.59% |
| NZX 50 Index | 13,059.74 | 150.74 | -1.14% |
| S&P 500 | 7,412.84 | 13.91 | 0.19% |
| S&P/ASX 200 | 8,683.00 | 28.30 | -0.32% |
| SSE Composite Index | 4,208.00 | 17.02 | -0.40% |